Henian Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Henian Chen has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
Stephanie Kasen
Columbia Univ, Dept Psychiat, New York, NY USA
5 shared publicationsYangxin Huang
Study Design and Data Analysis, College of Public Health, University of South FL
5 shared publicationsPatricia Cohen
From the Department of Epidemiology & Biostatistics (L. Chen, Huang, H. Chen), College of Public Health, University of South Florida, Tampa, Florida; Department of Biostatistics and Bioinformatics (L. Chen), H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida; Departments of Psychiatry (Kasen, Skodol, Cohen) and Epidemiology (Cohen), Columbia University, New York, New York; and Division of Epidemiology (Kasen, Cohen), New York State Psychiatric Institute, New York, New York
4 shared publicationsBiwei Cao
Department of Biostatistics and Data Science, College of Public Health University of South Florida Tampa Florida USA
3 shared publicationsNanhua Zhang
3 shared publicationsWei Wang
Centre for Addiction and Mental Health (CAMH)
3 shared publications
Latest Publications
- 14 August 2026
- Published by Elsevier in Journal of Cancer Policy
- Vol. 49
Geographic disparities, trial characteristics, and transparency of 3720 ovarian cancer clinical trials
- 14 August 2026
- Published by Elsevier in Journal of Cancer Policy
- Vol. 49
Geographic disparities, trial characteristics, and transparency of 3720 ovarian cancer clinical trials
- 20 February 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (7) , 1957-1964
Investigating started sample size, completed sample size and drop‐out rate in 10 252 phase III clinical trials: Insights from ClinicalTrials.gov
Aims: This study investigated the started sample size, completed sample size and drop‐out rate of 10 252 published and unpublished phase III clinical trials registered on ClinicalTrials.gov over the past 20 years. Methods: We conducted a comprehensive search on ClinicalTrials.gov for all phase III clinical trials with registered results before 26 May 2023. We retrieved and downloaded 10 252, which covered a period of more than 20 years. Results: Out of the 10 252 trials analysed, 889 (8.7%) were sponsored by the US National Institutes of Health/US Federal agencies (NIH/US Fed), 8429 (82.2%) were sponsored by industry. The overall median started sample size was 302. The overall median completed sample size was 228. The median completed sample sizes were 258 for industry‐sponsored trials, and 194 for NIH/US Fed‐sponsored trials. The median completed sample sizes were 321 for biological interventions and 223 for drug interventions. The overall median drop‐out rate was 11%. Statistically significant differences were observed in sample sizes between industry‐sponsored trials and NIH/US Fed‐sponsored trials ( P < 0.0001). Neither the started sample sizes nor the completed sample sizes have shown any change over the course of the past 20 years. Conclusions: Our findings indicate that a majority of the analysed trials lack sufficient statistical power (80%) to detect small effect sizes, and approximately half of the trials did not have 80% power to detect medium effect sizes. Notably, trials funded by NIH/US Fed exhibit significantly smaller sample sizes compared to trials sponsored by industry. When conducting sample size calculations for clinical trials, it is crucial to consider the anticipated effect size, variability and drop‐out rate.
- 20 February 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (7) , 1957-1964
Investigating started sample size, completed sample size and drop‐out rate in 10 252 phase III clinical trials: Insights from ClinicalTrials.gov
Aims: This study investigated the started sample size, completed sample size and drop‐out rate of 10 252 published and unpublished phase III clinical trials registered on ClinicalTrials.gov over the past 20 years. Methods: We conducted a comprehensive search on ClinicalTrials.gov for all phase III clinical trials with registered results before 26 May 2023. We retrieved and downloaded 10 252, which covered a period of more than 20 years. Results: Out of the 10 252 trials analysed, 889 (8.7%) were sponsored by the US National Institutes of Health/US Federal agencies (NIH/US Fed), 8429 (82.2%) were sponsored by industry. The overall median started sample size was 302. The overall median completed sample size was 228. The median completed sample sizes were 258 for industry‐sponsored trials, and 194 for NIH/US Fed‐sponsored trials. The median completed sample sizes were 321 for biological interventions and 223 for drug interventions. The overall median drop‐out rate was 11%. Statistically significant differences were observed in sample sizes between industry‐sponsored trials and NIH/US Fed‐sponsored trials ( P < 0.0001). Neither the started sample sizes nor the completed sample sizes have shown any change over the course of the past 20 years. Conclusions: Our findings indicate that a majority of the analysed trials lack sufficient statistical power (80%) to detect small effect sizes, and approximately half of the trials did not have 80% power to detect medium effect sizes. Notably, trials funded by NIH/US Fed exhibit significantly smaller sample sizes compared to trials sponsored by industry. When conducting sample size calculations for clinical trials, it is crucial to consider the anticipated effect size, variability and drop‐out rate.
- Open Access
- 29 May 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (5) , e0301917
Breaking the silence of sharing data in medical research
Data sharing is highly advocated in the scientific community, with numerous organizations, funding agencies, and journals promoting transparency and collaboration. However, limited research exists on actual data sharing practices. We conducted a comprehensive analysis of the intent to share individual participant data (IPD) in a total of 313,990 studies encompassing clinical trials and observational studies obtained from ClinicalTrials.gov, spanning the period from 2000 to 2023. Our study found that only 10.3% of principal investigators (PIs) expressed intent to share IPD. Clinical trials were more likely to share data than observational studies (odds ratio, OR = 1.98, 95% CI: 1.92–2.04). Large sample size studies were 1.69 times more likely to share data than small ones (95% CI: 1.65–1.73). Studies registered after 2018 were 1.6 times more likely to share data (95% CI: 1.57–1.64) than before 2019. NIH and other US Federal agency-funded studies had 1.49 times higher odds of sharing data (95% CI: 1.43–1.55) than other funders. USA-based studies were 1.53 times more likely to share data (95% CI: 1.49–1.57) than out of USA. Biological trials were 1.58 times more likely to share data than drug and other trials (95% CI: 1.51–1.66). Phase III trials had the highest odds, 2.47 times, of sharing data (95% CI: 2.38–2.56) than non-Phase III trials.
- 29 May 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (5) , e0301917
Open AccessBreaking the silence of sharing data in medical research
Data sharing is highly advocated in the scientific community, with numerous organizations, funding agencies, and journals promoting transparency and collaboration. However, limited research exists on actual data sharing practices. We conducted a comprehensive analysis of the intent to share individual participant data (IPD) in a total of 313,990 studies encompassing clinical trials and observational studies obtained from ClinicalTrials.gov, spanning the period from 2000 to 2023. Our study found that only 10.3% of principal investigators (PIs) expressed intent to share IPD. Clinical trials were more likely to share data than observational studies (odds ratio, OR = 1.98, 95% CI: 1.92–2.04). Large sample size studies were 1.69 times more likely to share data than small ones (95% CI: 1.65–1.73). Studies registered after 2018 were 1.6 times more likely to share data (95% CI: 1.57–1.64) than before 2019. NIH and other US Federal agency-funded studies had 1.49 times higher odds of sharing data (95% CI: 1.43–1.55) than other funders. USA-based studies were 1.53 times more likely to share data (95% CI: 1.49–1.57) than out of USA. Biological trials were 1.58 times more likely to share data than drug and other trials (95% CI: 1.51–1.66). Phase III trials had the highest odds, 2.47 times, of sharing data (95% CI: 2.38–2.56) than non-Phase III trials.
- 8 March 2024
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 31 (5) , 1135-1143
A data-driven approach to choosing privacy parameters for clinical trial data sharing under differential privacy
Objectives: Clinical trial data sharing is crucial for promoting transparency and collaborative efforts in medical research. Differential privacy (DP) is a formal statistical technique for anonymizing shared data that balances privacy of individual records and accuracy of replicated results through a “privacy budget” parameter, ε. DP is considered the state of the art in privacy-protected data publication and is underutilized in clinical trial data sharing. This study is focused on identifying ε values for the sharing of clinical trial data.Materials and Methods: We analyzed 2 clinical trial datasets with privacy budget ε ranging from 0.01 to 10. Smaller values of ε entail adding greater amounts of random noise, with better privacy as a result. Comparison of rates, odds ratios, means, and mean differences between the original clinical trial datasets and the empirical distribution of the DP estimator was performed.Results: The DP rate closely approximated the original rate of 6.5% when ε > 1. The DP odds ratio closely aligned with the original odds ratio of 0.689 when ε ≥ 3. The DP mean closely approximated the original mean of 164.64 when ε ≥ 1. As ε increased to 5, both the minimum and maximum DP means converged toward the original mean.Discussion: There is no consensus on how to choose the privacy budget ε. The definition of DP does not specify the required level of privacy, and there is no established formula for determining ε.Conclusion: Our findings suggest that the application of DP holds promise in the context of sharing clinical trial data.
- 8 March 2024
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 31 (5) , 1135-1143
A data-driven approach to choosing privacy parameters for clinical trial data sharing under differential privacy
Objectives: Clinical trial data sharing is crucial for promoting transparency and collaborative efforts in medical research. Differential privacy (DP) is a formal statistical technique for anonymizing shared data that balances privacy of individual records and accuracy of replicated results through a “privacy budget” parameter, ε. DP is considered the state of the art in privacy-protected data publication and is underutilized in clinical trial data sharing. This study is focused on identifying ε values for the sharing of clinical trial data.Materials and Methods: We analyzed 2 clinical trial datasets with privacy budget ε ranging from 0.01 to 10. Smaller values of ε entail adding greater amounts of random noise, with better privacy as a result. Comparison of rates, odds ratios, means, and mean differences between the original clinical trial datasets and the empirical distribution of the DP estimator was performed.Results: The DP rate closely approximated the original rate of 6.5% when ε > 1. The DP odds ratio closely aligned with the original odds ratio of 0.689 when ε ≥ 3. The DP mean closely approximated the original mean of 164.64 when ε ≥ 1. As ε increased to 5, both the minimum and maximum DP means converged toward the original mean.Discussion: There is no consensus on how to choose the privacy budget ε. The definition of DP does not specify the required level of privacy, and there is no established formula for determining ε.Conclusion: Our findings suggest that the application of DP holds promise in the context of sharing clinical trial data.
- 16 February 2024
- Published by Taylor & Francis in Communications in Statistics - Simulation and Computation
- Vol. 54 (7) , 2646-2663
Adjustment of selection bias for clinical trials: a simulation study
- 16 February 2024
- Published by Taylor & Francis in Communications in Statistics - Simulation and Computation
- Vol. 54 (7) , 2646-2663
Adjustment of selection bias for clinical trials: a simulation study
- 20 October 2023
- Published by Springer Nature in Child & Youth Care Forum
- Vol. 53 (4) , 801-823
The Roles of Therapeutic Alliance and Negative Cognitions in Parent-Led Treatment Versus Standard Care Therapy for Posttraumatic Stress
- 20 October 2023
- Published by Springer Nature in Child & Youth Care Forum
- Vol. 53 (4) , 801-823
The Roles of Therapeutic Alliance and Negative Cognitions in Parent-Led Treatment Versus Standard Care Therapy for Posttraumatic Stress
- 11 January 2022
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 61 (8) , 1010-1022.e4
Stepped Care Versus Standard Care for Children After Trauma: A Randomized Non-Inferiority Clinical Trial
- 11 January 2022
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 61 (8) , 1010-1022.e4
Stepped Care Versus Standard Care for Children After Trauma: A Randomized Non-Inferiority Clinical Trial
- 1 November 2021
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 110, 106475
A tailored telehealth group tobacco cessation treatment program for people with HIV: Study protocol for a randomized controlled trial
- 1 November 2021
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 110, 106475
A tailored telehealth group tobacco cessation treatment program for people with HIV: Study protocol for a randomized controlled trial
- Open Access
- 22 March 2021
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 50 (5) , 1699-1708
The effect of opioids on the cognitive function of older adults: results from the Personality and Total Health through life study
Chronic pain, a common complaint among older adults, affects physical and mental well-being. While opioid use for pain management has increased over the years, pain management in older adults remains challenging, due to potential severe adverse effects of opioids in this population. we examined the association between opioid use, and changes in cognitive function of older adults. prospective study. community dwelling older adults. study population consisted of 2,222 individuals aged 65–69 years at baseline from the Personality and Total Health Through Life Study in Australia. medication data were obtained from the Pharmaceutical Benefits Scheme. Cognitive measures were obtained from neuropsychological battery assessment. Opioid exposure was quantified as Total Morphine Equivalent Dose (MED). The association between change in cognitive function between Wave 2 and Wave 3, and cumulative opioid use was assessed through generalized linear models. cumulative opioid exposure exceeding total MED of 2,940 was significantly associated with poorer performance in the Mini Mental State Examination (MMSE). Compared with those not on opioids, individuals exposed to opioids resulting in cumulative total MED of greater than 2,940 had significantly lower scores in the MMSE (Model 1: β = −0.34, Model 2: β = −0.35 and Model 3: β = −0.39, P < 0.01). Performance in other cognitive assessments was not associated with opioid use. prolonged opioid use in older adults can affect cognitive function, further encouraging the need for alternative pain management strategies in this population. Pain management options should not adversely affect healthy ageing trajectories and cognitive health.
- 22 March 2021
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 50 (5) , 1699-1708
Open AccessThe effect of opioids on the cognitive function of older adults: results from the Personality and Total Health through life study
Chronic pain, a common complaint among older adults, affects physical and mental well-being. While opioid use for pain management has increased over the years, pain management in older adults remains challenging, due to potential severe adverse effects of opioids in this population. we examined the association between opioid use, and changes in cognitive function of older adults. prospective study. community dwelling older adults. study population consisted of 2,222 individuals aged 65–69 years at baseline from the Personality and Total Health Through Life Study in Australia. medication data were obtained from the Pharmaceutical Benefits Scheme. Cognitive measures were obtained from neuropsychological battery assessment. Opioid exposure was quantified as Total Morphine Equivalent Dose (MED). The association between change in cognitive function between Wave 2 and Wave 3, and cumulative opioid use was assessed through generalized linear models. cumulative opioid exposure exceeding total MED of 2,940 was significantly associated with poorer performance in the Mini Mental State Examination (MMSE). Compared with those not on opioids, individuals exposed to opioids resulting in cumulative total MED of greater than 2,940 had significantly lower scores in the MMSE (Model 1: β = −0.34, Model 2: β = −0.35 and Model 3: β = −0.39, P < 0.01). Performance in other cognitive assessments was not associated with opioid use. prolonged opioid use in older adults can affect cognitive function, further encouraging the need for alternative pain management strategies in this population. Pain management options should not adversely affect healthy ageing trajectories and cognitive health.